Actoplus Met: Dual-Action Control for Type 2 Diabetes Management
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.44 | $43.17 (0%) | 🛒 Add to cart |
| 60 | $1.17 | $86.34 $70.28 (19%) | 🛒 Add to cart |
| 90 | $1.09 | $129.52 $98.39 (24%) | 🛒 Add to cart |
| 120 | $1.05 | $172.69 $125.50 (27%) | 🛒 Add to cart |
| 180 | $1.00 | $259.03 $179.72 (31%) | 🛒 Add to cart |
| 270 | $0.97 | $388.55 $262.05 (33%) | 🛒 Add to cart |
| 360 | $0.96
Best per pill | $518.07 $344.37 (34%) | 🛒 Add to cart |
Synonyms
| |||
Actoplus Met combines two proven antidiabetic agents, pioglitazone and metformin hydrochloride, into a single, convenient tablet. This medication is specifically formulated for the management of type 2 diabetes mellitus in adults, particularly when diet and exercise alone, or monotherapy with either metformin or a thiazolidinedione, have provided inadequate glycemic control. It works by addressing two key pathophysiological defects of type 2 diabetes: insulin resistance in muscle and adipose tissue and reduced insulin secretion by the pancreatic beta-cells. By improving the body’s sensitivity to insulin and decreasing hepatic glucose production, Actoplus Met offers a comprehensive approach to lowering both fasting and postprandial blood glucose levels.
Features
- Dual-Mechanism Formulation: Contains pioglitazone HCl (a thiazolidinedione) and metformin HCl (a biguanide) for complementary action.
- Available Strengths: Tablets are available in three fixed-dose combinations: 15 mg pioglitazone/500 mg metformin, 15 mg pioglitazone/850 mg metformin, and 30 mg pioglitazone/1000 mg metformin.
- Oral Administration: Designed for convenient twice-daily oral intake with meals.
- Prescription Medication: Available only under the supervision of a qualified healthcare professional.
Benefits
- Provides superior glycemic control compared to either component alone, as demonstrated in clinical trials.
- Effectively lowers both HbA1c (glycated hemoglobin) and fasting plasma glucose (FPG) levels.
- Improves insulin sensitivity in peripheral tissues, helping the body utilize its own insulin more effectively.
- Reduces hepatic glucose output, a major contributor to elevated fasting blood sugar.
- Offers the convenience of a combination therapy, which may reduce pill burden and improve adherence for patients requiring multiple agents.
- Can be a valuable therapeutic option when metformin monotherapy reaches its efficacy limit.
Common use
Actoplus Met is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is commonly prescribed in cases where:
- Previous treatment with metformin alone has not achieved target blood glucose levels.
- Previous treatment with a thiazolidinedione (like pioglitazone) alone has not achieved target blood glucose levels.
- A patient already stabilized on combination therapy with both pioglitazone and metformin as separate tablets is being switched to this combination product for convenience. It is not for the treatment of type 1 diabetes or diabetic ketoacidosis.
Dosage and direction
The dosage of Actoplus Met must be individualized based on the patient’s current regimen, effectiveness, and tolerability, always under a physician’s direction.
- Initial Dose: For patients not currently on metformin, the starting dose is typically one 15 mg/500 mg tablet twice daily with meals to minimize gastrointestinal side effects associated with metformin. The starting dose for patients inadequately controlled on metformin or pioglitazone monotherapy will be based on their current doses.
- Titration: Dose escalation should be gradual to reduce gastrointestinal effects. Dosage adjustments should be based on blood glucose measurements, usually at intervals of no less than one to two weeks.
- Maximum Dose: The maximum recommended daily dose is 45 mg of pioglitazone and 2550 mg of metformin (e.g., one 15 mg/850 mg tablet three times daily or other combinations that do not exceed these limits). The daily dose of pioglitazone should not exceed 45 mg.
- Administration: Tablets should be swallowed whole with a meal and a full glass of water. Do not crush or chew.
Precautions
- Lactic Acidosis: A rare but serious metabolic complication that can occur due to metformin accumulation. Risk factors include renal impairment, congestive heart failure requiring pharmacologic treatment, advanced age, dehydration, excessive alcohol intake, hepatic impairment, and acute conditions that can affect renal function (e.g., infection, shock, radiocontrast administration). Symptoms include malaise, myalgia, respiratory distress, somnolence, and abdominal pain. Discontinue drug immediately if suspected.
- Cardiac Failure: Thiazolidinediones, including pioglitazone, can cause fluid retention, which may exacerbate or lead to congestive heart failure. Monitor patients for signs and symptoms of heart failure (e.g., rapid weight gain, edema, dyspnea).
- Hepatic Effects: Drug-induced hepatotoxicity has been reported with other thiazolidinediones. Perform liver enzyme tests prior to initiation and periodically per clinical guidance. Do not initiate therapy in patients with active liver disease or ALT levels >2.5X ULN.
- Hypoglycemia: Risk increases when used in combination with other glucose-lowering agents, such as sulfonylureas or insulin.
- Vitamin B12 Deficiency: Long-term use of metformin has been associated with vitamin B12 deficiency. Monitor hematological parameters periodically.
- Ovulation: Pioglitazone may result in ovulation in premenopausal anovulatory women, increasing the risk of pregnancy. Adequate contraception should be recommended.
- Bladder Cancer: Epidemiological studies suggested an increased risk of bladder cancer with pioglitazone use. Do not use in patients with active bladder cancer; use with caution in patients with a prior history.
Contraindications
Actoplus Met is contraindicated in patients with:
- Severe renal impairment (eGFR below 30 mL/min/1.73 m²) or renal disease.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
- History of a hypersensitivity reaction to pioglitazone, metformin, or any other component of the formulation.
- Acute or unstable congestive heart failure requiring pharmacological intervention.
Possible side effect
Common side effects (>5%) are often related to the metformin component and may include:
- Diarrhea
- Nausea/Vomiting
- Flatulence
- Abdominal discomfort
- Headache Other important side effects include:
- Pioglitazone-related: Edema (fluid retention), weight gain, upper respiratory tract infection, myalgia (muscle pain), hypoglycemia (especially when combined with other agents).
- Metformin-related: Lactic acidosis (rare but serious), metallic taste, vitamin B12 deficiency.
- Other: Potential increased risk of bone fractures (particularly in women), increased LDL cholesterol, and bladder cancer (see Precautions).
Drug interaction
Concomitant use of Actoplus Met with other drugs requires careful monitoring:
- Drugs that impair renal function (e.g., NSAIDs, certain antihypertensives): Can increase the risk of metformin accumulation and lactic acidosis.
- Alcohol: Potentiates the effect of metformin on lactate metabolism and increases the risk of lactic acidosis. Alcohol consumption should be avoided.
- Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, trimethoprim, vancomycin): Compete with metformin for renal tubular secretion and may increase metformin blood levels.
- Other hypoglycemic agents (e.g., sulfonylureas, insulin): Increase the risk of hypoglycemia. Dose reduction of the concomitant agent may be necessary.
- Enzyme Inducers/Inhibitors: Pioglitazone is primarily metabolized by CYP2C8 and to a lesser extent CYP3A4. Co-administration with strong inducers (e.g., rifampin) or inhibitors (e.g., gemfibrozil) of these enzymes may alter pioglitazone concentrations.
Missed dose
- If a dose is missed, it should be taken as soon as the patient remembers, unless it is almost time for the next scheduled dose.
- Do not double the dose to make up for a missed one.
- Resume the regular dosing schedule with the next meal.
Overdose
- Metformin Overdose: Hypoglycemia has been reported but is uncommon. The primary concern is lactic acidosis, which is a medical emergency characterized by electrolyte disturbances and an elevated blood lactate level. Hospitalization is immediate and essential. Hemodialysis is effective for correcting acidosis and removing accumulated metformin.
- Pioglitazone Overdose: Limited data exists. Expected effects may include exaggerated side effects such as edema and hypoglycemia. Supportive and symptomatic treatment is indicated.
- In all cases of suspected overdose, immediate medical attention must be sought.
Storage
- Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
- Keep the bottle tightly closed to protect from moisture and light.
- Keep out of reach of children and pets.
- Do not use after the expiration date printed on the bottle.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various sources believed to be accurate but cannot be guaranteed. The author and publisher disclaim any liability for any adverse effects resulting directly or indirectly from the use of the information contained herein.
Reviews
- “As an endocrinologist, Actoplus Met has been a valuable tool in my arsenal for patients struggling with metformin monotherapy. The dual mechanism provides a robust HbA1c reduction, and the fixed-dose combination improves adherence. I am always vigilant for signs of fluid retention.” – Dr. E. Vance, MD, Endocrinology
- “Clinical trial data consistently shows the additive effect of combining a TZD with metformin. This formulation captures that synergy effectively. The key is careful patient selection, excluding those with any cardiac or renal risk factors.” – Clinical Pharmacist Review
- “From a patient perspective, switching from two pills to one was a welcome change. It simplified my routine. I experienced some initial stomach upset, but it subsided after a few weeks. My glucose readings have been much more stable.” – Anonymous Patient Feedback (Compiled)
- “This is a potent combination that requires thorough patient education. The risks of lactic acidosis and CHF, while low with proper screening, are serious. It is not a first-line agent but serves an important role in the stepwise management of type 2 diabetes.” – Diabetes Educator Journal